Search | Clinical Trials Finder

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more

Conditions: Acne Vulgaris
Interventions: Adapalene Gel 0.1%, Placebo Control, Differin® Gel (Adapalene 0.1%, Galderma); Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 978 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Atopic Dermatitis Eczema
Interventions: Roflumilast Cream 0.15%, Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 42
States / cities: Montgomery, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 37 more

Conditions: Knee Osteoarthritis
Interventions: Lorecivivint, Placebo; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 99
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 85 more

Conditions: Acne Vulgaris
Interventions: GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion; Drug
Lead sponsor: Balmoral Medical company; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 34
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more

Conditions: Hidradenitis Suppurativa
Interventions: Ruxolitinib cream, Vehicle cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Phoenix, Arizona • Fountain Valley, California • Boca Raton, Florida + 12 more

Conditions: Benign Prostatic Hyperplasia
Interventions: PRX302, Placebo; Drug · Other
Lead sponsor: Sophiris Bio Corp; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 45
States / cities: Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 40 more

Conditions: Hyperhidrosis
Interventions: glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%, glycopyrrolate, 4.0%, Vehicle; Drug · Other
Lead sponsor: Journey Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 21
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Encinitas, California + 17 more

Conditions: Non-melanomatous Skin Cancer
Interventions: imiquimod, conventional surgery; Drug · Procedure
Lead sponsor: National Naval Medical Center; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: IDP-124 Lotion, IDP-124 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Ocular Redness
Interventions: Placebo, Brimonidine tartrate 0.025%; Drug
Lead sponsor: Eye Therapies, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Eye
Interventions: VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle; Drug
Lead sponsor: VivaVision Biotech, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pain, Postoperative
Interventions: XaraColl, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 23
States / cities: Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more

Conditions: Acne Vulgaris
Interventions: IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel, IDP 120 Vehicle Gel; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 364 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 20
States / cities: Encino, California • Lake Mary, Florida • Miami, Florida + 15 more

Conditions: Rosacea
Interventions: Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more

Conditions: Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions: Thymosin Beta 4 eye drops, Vehicle Control; Drug
Lead sponsor: Michigan Cornea Consultants, PC; Other
Eligibility: 18 Years to 90 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Healthy
Interventions: azelaic acid pre foam formulation, Vehicle pre foam formulation, Water; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Surgery
Interventions: 2% CHG Cloth solution, Vehicle Cloth, Active Comparator, Saline, SLS; Drug · Device · Other
Lead sponsor: Medline Industries; Industry
Eligibility: 16 Years and older
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Butte, Montana

Conditions: Chronic Migraine
Interventions: LBR-101 High Dose, LBR-101 Low Dose, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 57
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 51 more

Conditions: Dry Eye
Interventions: Ketorolac/HPMC, HPMC, Vehicle; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Diabetic Macular Edema
Interventions: Sirolimus, Placebo; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Stress Urinary Incontinence
Interventions: AMDC-USR (iltamiocel), Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 20
States / cities: Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more

Conditions: Ocular Infections, Irritations and Inflammations
Interventions: KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%, Vehicle of KPI-121 1.0%; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 23
States / cities: Artesia, California • Mission Hills, California • Rancho Cordova, California + 17 more

Conditions: Screen Time Exposure
Interventions: Human-developed negative body image warning, Voluntary warning, Human-developed depression and anxiety warning, Human-developed addiction warning, Human-developed sleep warning, Human-developed mental health harms to young people warning, Human-developed warning that social media has not been proven safe, Control message, California's proposed social media warning, Artificial-intelligence-developed depression and anxiety warning, Artificial-intelligence-developed negative body image warning, Artificial-intelligence-developed addiction warning, Artificial-intelligence-developed sleep warning, Artificial-intelligence-developed mental health harms to young people warning, Artificial-intelligence-developed warning that social media has not been proven safe; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 29 Years
Enrollment: 1,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation

Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth

Assessment of LBR-101 In Chronic Migraine

Efficacy Study of Ketorolac and HPMC to Treat Dry Eye

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

Reactions to Social Media Warning Labels Among Teens and Young Adults